Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Conjunctival Neoplasms

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Conjunctival Neoplasms:

Pubmed Logo
Management of conjunctival melanoma.
Invasive conjunctival melanoma can arise de novo, from nevus or from...
18th November, 2009
Ocular Oncology Service, Royal Liverpool University Hospital, Prescot Expert Rev Anticancer Ther. 2009 Sep;9(9):1227-39.
DOI Direct Link
Demographics, etiology, and behavior of conjunctival squamous cell carcinoma in the 21st century.
PURPOSE: T-helper 17 lymphocytes (Th17) were identified in the healthy...
13th November, 2009
Ophthalmology. 2009 Nov;116(11):2045-6.
DOI Direct Link
Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients.
PURPOSE: To report the findings on sentinel lymph node biopsy (SLNB) in 30...
13th November, 2009
Section of Ophthalmology, Department of Head and Neck Surgery, The Ophthalmology. 2009 Nov;116(11):2217-23. Epub 2009 Sep 19.
DOI Direct Link
Comparison between PENELOPE and electron Monte Carlo simulations of electron fields used in the treatment of conjunctival lymphoma.
For the treatment of conjunctival lymphoma in the early stages, external...
11th November, 2009
NCTeam, Strahlenklinik, Universitatsklinikum Essen, Hufelandstr. 55, Essen Phys Med Biol. 2009 Sep 21;54(18):5469-81. Epub 2009 Aug 26.
DOI Direct Link
The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia.
PURPOSE: To determine the reliability and role of conjunctival exfoliative...
6th November, 2009
The New York Eye Cancer Center, New York, NY 10065, USA. Am J Ophthalmol. 2009 Nov;148(5):772-778.e1. Epub 2009 Aug 5.
DOI Direct Link

View more research publications.

Press Releases About Conjunctival Neoplasms:

BioPortfolio Logo
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 9th November, 2009 ISTA Pharmaceuticals, Inc.
MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the American College of Clinical Pharmacy (ACCP) 2009 Annual Meeting 21st October, 2009 ISTA Pharmaceuticals, Inc.
ANAHEIM, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting 7th May, 2009 ISTA Pharmaceuticals, Inc.
FT. LAUDERDALE, Fla., May 7 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today presented results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution)
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 4th May, 2009 Fovea Pharmaceuticals
PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays 4th May, 2009 Ipsogen SA
MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the

Conjunctival Neoplasms Patents:

USPTO Logo
US Patent No.Title
7517864 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
7514099 Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
7404969 Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
7232667 Keratinocyte growth factor-2 polynucleotides
7176304 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Conjunctival Neoplasms scientists - we have details of around 139 individuals working on Conjunctival Neoplasms .


This page has been viewed 343 times
Recent Search Terms used to find this page: bepotastine besilate ophthalmic patent | conjunctival neoplasms | conjunctival neoplasm | conjunctival neoplasm | what is conjunctival neoplasm | what is a neoplam conjunctiva | conjunctival neoplasms | conjunctival neoplasm | conjunctival neoplasm | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Conjunctival Neoplasms across BioPortfolio, or for Conjunctival Neoplasms Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.